NY-CLARITY-AI
2.8.2022 14:02:12 CEST | Business Wire | Press release
Clarity AI announced today that they have been named a leader in “The Forrester New Wave™: ESG Ratings, Data, And Analytics, Q3 2022.” Clarity AI received a differentiated rating, the highest score possible across 7 of the 10 criteria evaluated: Analytics Capabilities, Standards Integrity, Presentation, Connections/Integrations, Execution Roadmap, Market Approach, and Product Vision.
“We are thrilled to be included in this report, and we thank our clients for making themselves available to Forrester for open, transparent discussions about Clarity AI and our product and strategy,” said Angel Agudo, VP of Product and Member of the Board at Clarity AI. “We believe we are bringing the very best product to market, and to see us land in the Leader section of this report is both validating and humbling for us.”
Forrester’s take on Clarity AI includes the following:
- “Offers strong analytics and user presentation capabilities. Clarity AI makes it easy for users to assess individual companies’ ESG-driven impact and benchmark it against peers (to support EU taxonomy-aligned reporting, for example). The web application is particularly well-designed and easy for users to navigate and explore.”
- “Is the best fit for companies that need to manage lots of ESG data. Many of Clarity AI’s financial services clients use it to model ESG data from a huge universe of companies and financial instruments in order to create and test new products and optimize portfolios.”
Additionally, Clarity AI clients, whom the analyst team at Forrester interviewed, had the following to say:
- “They understood nuances that their competitors didn’t even know existed.”
- “It’s very easy to see a company’s alignment with technical standards.”
- “The process of connecting was seamless; it took only a month to get the API set up properly.”
A total of nine providers were evaluated in “The Forrester New Wave™: ESG Ratings, Data, And Analytics” report. Among the nine, the Forrester report cites that Clarity AI has the highest strategy score.
Mr. Agudo adds, “Forrester’s analysis provides a good view into the Clarity AI product vision and strategy that extends to our entire offering, which includes solutions and capabilities to cover Impact assessment, ESG risk assessment, carbon foot-printing, investment portfolio analysis, and the regulatory requirements, including associated reporting needs , associated with EU Taxonomy, SFDR and MiFID II, as well as the Paris Agreement (i.e., Net Zero) and the TCFD framework.”
About Clarity AI
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, companies, governments, and consumers. As of July 2022, Clarity AI’s platform analyzes more than 50,000 companies, 300,000 funds, 198 countries and 188 local governments – 2-3 times more than any other player in the market – and delivers data and analytics for investing, corporate research and reporting. Clarity AI has offices in North America, Europe and the Middle East, and its client network manages tens of trillions in assets under management. clarity.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom